Maat Pharma SA

MAAT · PA · Healthcare / Biotechnology

1.03EUR-0.03 (-3.02%)

Price History

Full chart

Market Stats

Previous Close1.06

Open1.08

Day Range1.02 – 1.08

52-Week Range1.00 – 8.62

Volume54.92K

Market Cap19.01M

P/E (TTM)0.00

Forward P/E0.00

EPS-1.90

Dividend Yield0.00%

Beta0.41

50-Day Avg2.44

200-Day Avg4.51

About

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. MaaT Pharma SA was incorporated in 2014 and is headquartered in Lyon, France.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Herve Affagard
Employees52
Headquarters70 Avenue Tony Garnier, Lyon, France, 69007, France
Websitehttps://www.maatpharma.com

Leadership

Mr. Herve AffagardCEO, Co-Founder & Director · b. 1974
Dr. Joel Dore Ph.D.Co-Founder & Member of Scientific Advisory Board
Mr. Pierre RimbaudCo-Founder
Mr. Eric Soyer Ph.D.Chief Financial Officer · b. 1966
Ms. Carole SchwintnerTechnology Director & Chief Technology Officer
Ms. Sheri Simmons Ph.D.Acting Chief Scientific Officer
Guilhaume Debroas Ph.D.Head of Investor Relations
Dr. Frederic Fasano M.B.A., Pharm.D.Chief Strategy & Corporate Development Officer · b. 1968
Ms. Sian CrouzetChief of Staff
Dr. Emilie Plantamura Ph.D., Pharm.D.Deputy Chief Medical Officer

Financials

Income Statement

Currency: EUR	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	109.32K	892.00K	89.30K	0	972.00K	1.43M	2.23M	3.22M	4.52M
Growth (%)	-	+715.95%	-89.99%	-100.00%	-	+47.12%	+55.80%	+44.34%	+40.67%
Cost of Revenue	3.50M	79.00K	97.00K	164.00K	166.00K	339.00K	1.44M	1.25M	3.13M
Gross Profit	-3.39M	813.00K	-7.70K	-164.00K	806.00K	1.09M	784.00K	1.97M	1.39M
Gross Margin	-3102.25%	91.14%	-8.62%	-	82.92%	76.29%	35.19%	61.13%	30.70%
Operating Expense	1.32M	5.22M	4.96M	7.22M	9.70M	14.65M	20.73M	30.39M	35.54M
Operating Income	-4.71M	-4.40M	-4.96M	-7.39M	-8.89M	-13.56M	-19.94M	-28.43M	-34.15M
Operating Margin	-4306.57%	-493.72%	-5559.66%	-	-914.92%	-947.97%	-895.11%	-883.96%	-754.86%
EBITDA	-4.66M	-5.09M	-6.08M	-6.58M	-8.57M	-13.10M	-22.07M	-26.34M	-32.41M
EBITDA Margin	-4259.74%	-570.85%	-6805.16%	-	-881.69%	-916.01%	-990.39%	-819.15%	-716.51%
Net Income	-3.86M	-4.55M	-6.65M	-5.35M	-9.02M	-13.71M	-19.72M	-28.90M	-31.06M
Net Income Margin	-3529.47%	-509.64%	-7443.12%	-	-927.88%	-958.95%	-884.96%	-898.76%	-686.58%
R&D	-	4.51M	5.27M	6.10M	9.14M	14.48M	20.30M	27.48M	27.58M
R&D as % of Total Revenue	-	505.49%	5900.07%	-	940.84%	1012.31%	911.00%	854.38%	609.62%
Interest Expense	0	71.00K	20.00K	45.00K	121.00K	201.00K	413.00K	868.00K	1.27M
Interest Expense % of Total Revenue	0.00%	7.96%	22.40%	-	12.45%	14.06%	18.54%	26.99%	28.05%

Balance Sheet

Currency: EUR	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	9.26M	5.88M	8.17M	24.28M	49.42M	44.73M	42.93M	38.50M	44.55M
Total Liabilities	3.99M	4.62M	12.73M	8.34M	9.56M	17.91M	22.46M	28.16M	42.75M
Total Equity	5.27M	1.27M	-4.57M	15.94M	39.86M	26.81M	20.47M	10.34M	1.80M
Cash	7.35M	3.60M	5.41M	19.91M	43.30M	35.25M	24.28M	20.15M	24.87M
Total Debt	1.72M	2.60M	10.46M	6.08M	5.81M	11.36M	14.07M	15.96M	17.44M
Net Debt	-5.63M	-998.00K	5.05M	-13.84M	-37.50M	-23.89M	-10.21M	-4.20M	-7.43M

Cash Flow

Currency: EUR	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-3.87M	-3.87M	-5.02M	-5.81M	-7.93M	-12.61M	-18.67M	-22.04M	-15.91M
Investing Cash Flow	-311.00K	-311.00K	-154.00K	-523.00K	-238.00K	-815.00K	-440.00K	-416.00K	-497.00K
Financing Cash Flow	432.00K	432.00K	6.98M	20.84M	31.56M	5.36M	8.14M	18.33M	21.12M
Capital Expenditure	291.00K	291.00K	128.00K	316.00K	238.00K	662.00K	1.09M	753.00K	609.00K
Free Cash Flow	-	-4.16M	-5.15M	-6.13M	-8.17M	-13.27M	-19.76M	-22.79M	-16.52M
FCF to OCF	-	107.52%	102.55%	105.44%	103.00%	105.25%	105.85%	103.42%	103.83%

Earnings

Report Date	Oct 20, 2021	Apr 14, 2022	Jul 28, 2022	Nov 8, 2022	Mar 30, 2023	May 9, 2023	Jul 27, 2023	Nov 9, 2023	Mar 28, 2024	Apr 2, 2024	Sep 19, 2024	Nov 5, 2024	Mar 27, 2025	Apr 14, 2025	Sep 17, 2025	Nov 4, 2025	Mar 30, 2026
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS Actual	-0.23	-0.48	-0.75	0.00	-0.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.15	-1.15	-1.00	0.00	0.00
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	Pre-market	Pre-market	After-hours	After-hours	-	After-hours	After-hours	After-hours	-	After-hours	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap19.01M

Enterprise Value16.00M

Trailing P/E0.00

Forward P/E0.00

Price / Sales5.98

Price / Book14.21

EPS-1.90

Book Value0.096

Revenue (TTM)3.18M

Gross Profit (TTM)2.13M

EBITDA-33.60M

Profit Margin0.00%

Operating Margin-1761.26%

Return on Equity-511.92%

Return on Assets-44.74%

Shares Outstanding18.82M

Shares Float11.04M

Beta0.41

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%